Exagen Inc.

XGN
NASDAQ
Last Updated: 12/5/2022 9:00:03 PM
Price
2.43
Changes
-0.06
% Change
-2.41
Volume
38942
52 Week
High
11.69
52 Week
Low
2.1
About Exagen Inc.
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Exagen Inc. Company Details
CEO:   Mr. Fortunato Rocca
Country:   US
Industry:   Diagnostics & Research
Website:   https://www.exagen.com
Exchange:   NASDAQ Global Market
IPO\Launch Date:   2019-09-19
Exagen Inc. Company Executive Details
  Mr. John Wegener
  Senior Vice President of Sales and Marketing
  Dr. Anja Kammesheidt Ph.D.
  Chief Scientific Officer
  Dr. Ming-Chou Lee Ph.D.
  Chief Technology Officer
  Mr. Mark Hazeltine
  Chief Operating Officer
  Dr. Debra Jeske Zack
  Chief Medical Officer

Exagen Inc. Latest News

Exagen Inc. (XGN) CEO John Aballi on Q3 2022 Results - Earnings Call Transcript


Exagen Inc. (NASDAQ:XGN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Mark Hazeltine - Chief Operating Officer Conference Call Participants Max Masucci - Cowen & Company Griffin Soriano - William Blair Kyle Mikson - Canaccord Genuity Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.


Published on: 2022-11-14 22:25:13

Impact on Symbol / Company: XGN

View News

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates


Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?


Published on: 2022-11-14 21:03:21

Impact on Symbol / Company: XGN

View News

Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022


SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022. John Aballi, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).


Published on: 2022-10-31 16:05:00

Impact on Symbol / Company: XGN

View News

Exagen Inc. (XGN) CEO Ron Rocca on Q2 2022 Results - Earnings Call Transcript


Exagen Inc. (NASDAQ:XGN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Griffin Soriano - William Blair Ross Osborn - Cantor Fitzgerald Ryan Douglas Good afternoon, and thank you for joining us today. Earlier today, Exagen Inc. released financial results for the quarter ended June 30th, 2022.


Published on: 2022-08-06 13:08:13

Impact on Symbol / Company: XGN

View News

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022


SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).


Published on: 2022-07-21 16:05:00

Impact on Symbol / Company: XGN

View News

Exagen Inc. (XGN) CEO Ron Rocca on Q1 2022 Results - Earnings Call Transcript


Exagen Inc. (NASDAQ:XGN ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Chief Operating Officer Conference Call Participants Brian Weinstein - William Blair Kyle Mikson - Canaccord Operator Greetings, ladies and gentlemen, and welcome to the Exagen, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this conference is being recorded.


Published on: 2022-05-11 20:41:17

Impact on Symbol / Company: XGN

View News

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates


Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?


Published on: 2022-05-11 19:34:17

Impact on Symbol / Company: XGN

View News

Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022


SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).


Published on: 2022-04-25 16:05:00

Impact on Symbol / Company: XGN

View News

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript


Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript


Published on: 2022-03-22 20:30:02

Impact on Symbol / Company: XGN

View News

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates


Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?


Published on: 2022-03-22 18:48:18

Impact on Symbol / Company: XGN

View News

Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022


SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2021 after the market close on Tuesday, March 22, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).


Published on: 2022-03-08 16:05:00

Impact on Symbol / Company: XGN

View News

Exagen Inc. (XGN) CEO Ron Rocca on Q3 2021 Results - Earnings Call Transcript


Exagen Inc. (XGN) CEO Ron Rocca on Q3 2021 Results - Earnings Call Transcript


Published on: 2021-11-13 12:48:02

Impact on Symbol / Company: XGN

View News

Grow your Money

We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures

Services we Offer

We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others

Live Market Data

We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you